| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD274 |
| Uniprot No | Q9NZQ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-238aa |
| 氨基酸序列 | FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNER |
| 预测分子量 | 52.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD274(PD-L1)重组蛋白的3篇代表性文献及其摘要内容：
---
1. **文献名称**：*Structural basis for cancer immunotherapy by the PD-L1/PD-1 interaction*
**作者**：Zak, K.M. et al.
**摘要**：本研究通过重组表达人源PD-L1蛋白，解析了其与PD-1结合的晶体结构，揭示了关键结合位点。实验表明，重组PD-L1蛋白可有效抑制T细胞激活，为基于结构的免疫检查点抑制剂设计提供了依据。
---
2. **文献名称**：*Recombinant PD-L1 protein enhances immunosuppressive function in vitro*
**作者**：Chen, L. & Dong, H.
**摘要**：作者在大肠杆菌中高效表达并纯化了功能性重组PD-L1蛋白。体外实验证实，该蛋白能与PD-1结合并显著抑制T细胞增殖与细胞因子分泌，验证了其在免疫调控中的关键作用。
---
3. **文献名称**：*Development of a PD-L1 recombinant protein-based assay for cancer biomarker detection*
**作者**：Topalian, S.L. et al.
**摘要**：研究利用哺乳动物细胞系统表达高纯度PD-L1重组蛋白，开发了一种新型ELISA检测方法，用于定量肿瘤患者血清中的可溶性PD-L1水平，为癌症免疫治疗的生物标志物研究提供了工具。
---
这些文献涵盖了重组CD274蛋白的结构解析、功能验证及临床应用开发，反映了其在基础研究与转化医学中的重要性。
CD274. also known as programmed death-ligand 1 (PD-L1), is a transmembrane protein that plays a critical role in modulating immune responses. It functions as an immune checkpoint molecule by binding to its receptor PD-1 (programmed cell death protein 1) on T-cells, delivering inhibitory signals that suppress T-cell activation and promote immune tolerance. This interaction is exploited by cancer cells and pathogens to evade immune surveillance, making CD274 a key therapeutic target in oncology and infectious diseases.
Recombinant CD274 protein is engineered through genetic modification, typically expressed in mammalian cells (e.g., HEK293 or CHO cells) or bacterial systems (e.g., E. coli) to produce soluble forms of the protein. The recombinant version often includes the extracellular domain of CD274. which retains PD-1 binding capacity, and may incorporate tags (e.g., Fc fusion or His-tag) for purification and detection. Its production enables standardized studies of PD-1/PD-L1 interactions in vitro, facilitating drug discovery and mechanistic research.
In research, recombinant CD274 is widely used to study immune checkpoint blockade therapies, screen monoclonal antibodies, and develop diagnostic assays. Clinically, inhibitors targeting the PD-1/PD-L1 axis (e.g., pembrolizumab, atezolizumab) have revolutionized cancer immunotherapy, underscoring the biomedical relevance of recombinant CD274 as a tool for characterizing drug candidates and understanding resistance mechanisms. Additionally, it serves as a critical reagent in vaccine development and autoimmune disease studies, where immune modulation is central.
×
